Home The Word Brain	My Amedeo FAQ Privacy About
	As of October 2023, Amedeo had 12,263 active subscribers

Prostate Cancer

Free Subscription Articles published in Br J Cancer Retrieve available abstracts of 82 articles: HTML format

Single Articles

November 2023
1. ZHAO JL, Antonarakis ES, Cheng HH, George DJ, et al
   Phase 1b study of enzalutamide plus CC-115, a dual mTORC1/2 and DNA-PK inhibitor, in men with metastatic castration-resistant prostate cancer (mCRPC).
   Br J Cancer. 2023 Nov 18. doi: 10.1038/s41416-023-02487.
   PubMed     Abstract available
   
   
   
2. SHEN J, Chowdhury S, Agarwal N, Karsh LI, et al
   Apalutamide efficacy, safety and wellbeing in older patients with advanced prostate cancer from Phase 3 randomised clinical studies TITAN and SPARTAN.
   Br J Cancer. 2023 Nov 11. doi: 10.1038/s41416-023-02492.
   PubMed     Abstract available
   
   
   
3. AHMAD AS, Offman J, Delon C, North BV, et al
   Years of life lost due to cancer in the United Kingdom from 1988 to 2017.
   Br J Cancer. 2023;129:1558-1568.
   PubMed     Abstract available
   
   
   
4. CAMERON JM, Sala A, Antoniou G, Brennan PM, et al
   A spectroscopic liquid biopsy for the earlier detection of multiple cancer types.
   Br J Cancer. 2023;129:1658-1666.
   PubMed     Abstract available
   
   
   
5. SHEN M, Liu S, Toland A, Hsu EC, et al
   ACAA2 is a novel molecular indicator for cancers with neuroendocrine phenotype.
   Br J Cancer. 2023;129:1818-1828.
   PubMed     Abstract available
   
   
   October 2023
6. FENG X, Zhang Y, Vaselkiv JB, Li R, et al
   Modifiable risk factors for subsequent lethal prostate cancer among men with an initially negative prostate biopsy.
   Br J Cancer. 2023 Oct 28. doi: 10.1038/s41416-023-02472.
   PubMed     Abstract available
   
   
   
7. TURPIN A, Delliaux C, Parent P, Chevalier H, et al
   Fascin-1 expression is associated with neuroendocrine prostate cancer and directly suppressed by androgen receptor.
   Br J Cancer. 2023 Oct 24. doi: 10.1038/s41416-023-02449.
   PubMed     Abstract available
   
   
   
8. GULLIVER C, Huss S, Semjonow A, Baillie GS, et al
   Loss of PDE4D7 expression promotes androgen independence, neuroendocrine differentiation and alterations in DNA repair: implications for therapeutic strategies.
   Br J Cancer. 2023;129:1462-1476.
   PubMed     Abstract available
   
   
   September 2023
9. HOU Y, Jiang KW, Wang LL, Zhi R, et al
   Biopsy-free AI-aided precision MRI assessment in prediction of prostate cancer biochemical recurrence.
   Br J Cancer. 2023 Sep 27. doi: 10.1038/s41416-023-02441.
   PubMed     Abstract available
   
   
   
10. HINNEH JA, Gillis JL, Mah CY, Irani S, et al
    Targeting hyaluronan-mediated motility receptor (HMMR) enhances response to androgen receptor signalling inhibitors in prostate cancer.
    Br J Cancer. 2023 Sep 6. doi: 10.1038/s41416-023-02406.
    PubMed     Abstract available
    
    
    August 2023
11. MACAULAY VM, Lord S, Hussain S, Maroto JP, et al
    A Phase Ib/II study of IGF-neutralising antibody xentuzumab with enzalutamide in metastatic castration-resistant prostate cancer.
    Br J Cancer. 2023 Aug 3. doi: 10.1038/s41416-023-02380.
    PubMed     Abstract available
    
    
    July 2023
12. HIRATA H, Hinoda Y, Shahryari V, Deng G, et al
    Editorial Expression of Concern: Genistein downregulates onco-miR-1260b and upregulates sFRP1 and Smad4 via demethylation and histone modification in prostate cancer cells.
    Br J Cancer. 2023 Jul 28. doi: 10.1038/s41416-023-02365.
    PubMed    
    
    
    
13. WANG A, Wan P, Hebert JR, Le Marchand L, et al
    Atopic allergic conditions and prostate cancer risk and survival in the Multiethnic Cohort study.
    Br J Cancer. 2023 Jul 24. doi: 10.1038/s41416-023-02364.
    PubMed     Abstract available
    
    
    
14. LI X, Chen Y, Bai L, Zhao R, et al
    Nicardipine is a putative EED inhibitor and has high selectivity and potency against chemoresistant prostate cancer in preclinical models.
    Br J Cancer. 2023 Jul 20. doi: 10.1038/s41416-023-02359.
    PubMed     Abstract available
    
    
    
15. CONTEDUCA V, Brighi N, Schepisi G, De Giorgi U, et al
    Immunogenomic profiles associated with response to life-prolonging agents in prostate cancer.
    Br J Cancer. 2023 Jul 13. doi: 10.1038/s41416-023-02354.
    PubMed     Abstract available
    
    
    
16. WATLING CZ, Kelly RK, Dunneram Y, Knuppel A, et al
    Associations of intakes of total protein, protein from dairy sources, and dietary calcium with risks of colorectal, breast, and prostate cancer: a prospective analysis in UK Biobank.
    Br J Cancer. 2023 Jul 5. doi: 10.1038/s41416-023-02339.
    PubMed     Abstract available
    
    
    May 2023
17. LANGLAIS CS, Graff RE, Van Blarigan EL, Neuhaus JM, et al
    Post-diagnostic health behaviour scores and risk of prostate cancer progression and mortality.
    Br J Cancer. 2023 May 22. doi: 10.1038/s41416-023-02283.
    PubMed     Abstract available
    
    
    
18. SALMON C, Quesnel-Vallee A, Barnett TA, Benedetti A, et al
    Neighbourhood social deprivation and risk of prostate cancer.
    Br J Cancer. 2023 May 15. doi: 10.1038/s41416-023-02299.
    PubMed     Abstract available
    
    
    April 2023
19. LAUTERT-DUTRA W, Dos Reis RB, Squire JA
    Precision medicine for prostate cancer-improved outcome prediction for low-intermediate risk disease using a six-gene copy number alteration classifier.
    Br J Cancer. 2023 Apr 29. doi: 10.1038/s41416-023-02289.
    PubMed     Abstract available
    
    
    
20. CHAN JSK, Satti DI, Lee YHA, Hui JMH, et al
    Temporal trends in cardiovascular burden among patients with prostate cancer receiving androgen deprivation therapy: a population-based cohort study.
    Br J Cancer. 2023 Apr 19. doi: 10.1038/s41416-023-02271.
    PubMed     Abstract available
    
    
    
21. CONSTANTIN TA, Varela-Carver A, Greenland KK, de Almeida GS, et al
    The CDK7 inhibitor CT7001 (Samuraciclib) targets proliferation pathways to inhibit advanced prostate cancer.
    Br J Cancer. 2023 Apr 19. doi: 10.1038/s41416-023-02252.
    PubMed     Abstract available
    
    
    
22. EBRAHIMIZADEH W, Guerard KP, Rouzbeh S, Scarlata E, et al
    A DNA copy number alteration classifier as a prognostic tool for prostate cancer patients.
    Br J Cancer. 2023 Apr 10. doi: 10.1038/s41416-023-02236.
    PubMed     Abstract available
    
    
    March 2023
23. TIBBO AJ, Hartley A, Vasan R, Shaw R, et al
    MBTPS2 acts as a regulator of lipogenesis and cholesterol synthesis through SREBP signalling in prostate cancer.
    Br J Cancer. 2023 Mar 29. doi: 10.1038/s41416-023-02237.
    PubMed     Abstract available
    
    
    
24. ZHOU Q, Ou Y, Dai X, Chen X, et al
    Correction to: Prevalence of tumour-infiltrating CD103(+) cells identifies therapeutic-sensitive prostate cancer with poor clinical outcome.
    Br J Cancer. 2023 Mar 20. doi: 10.1038/s41416-023-02211.
    PubMed    
    
    
    February 2023
25. ZHOU Q, Ou Y, Dai X, Chen X, et al
    Prevalence of tumour-infiltrating CD103(+) cells identifies therapeutic-sensitive prostate cancer with poor clinical outcome.
    Br J Cancer. 2023 Feb 9. doi: 10.1038/s41416-023-02183.
    PubMed     Abstract available
    
    
    January 2023
26. TAO W, Luo ZH, He YD, Wang BY, et al
    Plasma extracellular vesicle circRNA signature and resistance to abiraterone in metastatic castration-resistant prostate cancer.
    Br J Cancer. 2023 Jan 26. doi: 10.1038/s41416-023-02147.
    PubMed     Abstract available
    
    
    
27. LI J, Liu N, Zhou H, Xian P, et al
    Immunoproteasome inhibition prevents progression of castration-resistant prostate cancer.
    Br J Cancer. 2023 Jan 21. doi: 10.1038/s41416-022-02129.
    PubMed     Abstract available
    
    
    
28. BAO J, Hou Y, Qin L, Zhi R, et al
    High-throughput precision MRI assessment with integrated stack-ensemble deep learning can enhance the preoperative prediction of prostate cancer Gleason grade.
    Br J Cancer. 2023 Jan 17. doi: 10.1038/s41416-022-02134.
    PubMed     Abstract available
    
    
    
29. LIN J, Nousome D, Jiang J, Chesnut GT, et al
    Five-year survival of patients with late-stage prostate cancer: comparison of the Military Health System and the U.S. general population.
    Br J Cancer. 2023 Jan 6. doi: 10.1038/s41416-022-02136.
    PubMed     Abstract available
    
    
    
30. YU R, Jiang KW, Bao J, Hou Y, et al
    PI-RADS(AI): introducing a new human-in-the-loop AI model for prostate cancer diagnosis based on MRI.
    Br J Cancer. 2023 Jan 4. doi: 10.1038/s41416-022-02137.
    PubMed     Abstract available
    
    
    December 2022
31. CARDOSO M, Maia S, Brandao A, Sahasrabudhe R, et al
    Exome sequencing of affected duos and trios uncovers PRUNE2 as a novel prostate cancer predisposition gene.
    Br J Cancer. 2022 Dec 23. doi: 10.1038/s41416-022-02125.
    PubMed     Abstract available
    
    
    
32. BLANC C, Moktefi A, Jolly A, de la Grange P, et al
    The Neuropilin-1/PKC axis promotes neuroendocrine differentiation and drug resistance of prostate cancer.
    Br J Cancer. 2022 Dec 22. doi: 10.1038/s41416-022-02114.
    PubMed     Abstract available
    
    
    
33. GREEN HD, Merriel SWD, Oram RA, Ruth KS, et al
    Response to: Genetic risk scores may compound rather than solve the issue of prostate cancer overdiagnosis (BJC-LT3342090).
    Br J Cancer. 2022 Dec 19. doi: 10.1038/s41416-022-02081.
    PubMed    
    
    
    
34. LIN E, Garmo H, Hagstrom E, Van Hemelrijck M, et al
    Association between atherogenic lipids and GnRH agonists for prostate cancer in men with T2DM: a nationwide, population-based cohort study in Sweden.
    Br J Cancer. 2022 Dec 15. doi: 10.1038/s41416-022-02091.
    PubMed     Abstract available
    
    
    
35. HARTLEY A, Ahmad I
    The role of PPARgamma in prostate cancer development and progression.
    Br J Cancer. 2022 Dec 12. doi: 10.1038/s41416-022-02096.
    PubMed     Abstract available
    
    
    
36. PEDERZOLI F, Raffo M, Pakula H, Ravera F, et al
    "Stromal cells in prostate cancer pathobiology: friends or foes?".
    Br J Cancer. 2022 Dec 8. doi: 10.1038/s41416-022-02085.
    PubMed     Abstract available
    
    
    November 2022
37. HORTON RH, Dunlop MG, Houlston RS, Lucassen A, et al
    Genetic risk scores may compound rather than solve the issue of prostate cancer overdiagnosis.
    Br J Cancer. 2022 Nov 28. doi: 10.1038/s41416-022-02080.
    PubMed    
    
    
    
38. ROULEAU M, Nguyen Van Long F, Turcotte V, Caron P, et al
    Extensive metabolic consequences of human glycosyltransferase gene knockouts in prostate cancer.
    Br J Cancer. 2022 Nov 8. pii: 10.1038/s41416-022-02040.
    PubMed     Abstract available
    
    
    
39. EGGER S, Smith DP, Patel MI, Kimlin MG, et al
    Cutaneous melanoma, prostate-specific antigen testing and the subsequent risk of prostate cancer diagnosis: a prospective analysis of the 45 and Up Study.
    Br J Cancer. 2022 Nov 1. pii: 10.1038/s41416-022-02027.
    PubMed     Abstract available
    
    
    October 2022
40. LAN T, Park Y, Colditz GA, Liu J, et al
    Adolescent dietary patterns in relation to later prostate cancer risk and mortality in the NIH-AARP Diet and Health Study.
    Br J Cancer. 2022 Oct 31. pii: 10.1038/s41416-022-02035.
    PubMed     Abstract available
    
    
    
41. BUTLER EN, Zhou CK, Curry M, McMenamin U, et al
    Testosterone therapy and cancer risks among men in the SEER-Medicare linked database.
    Br J Cancer. 2022 Oct 28. pii: 10.1038/s41416-022-02019.
    PubMed     Abstract available
    
    
    
42. RODRIGUEZ-VIDA A, Maroto P, Font A, Martin C, et al
    Safety and efficacy of avelumab plus carboplatin in patients with metastatic castration-resistant prostate cancer in an open-label Phase Ib study.
    Br J Cancer. 2022 Oct 26. pii: 10.1038/s41416-022-01991.
    PubMed     Abstract available
    
    
    
43. CROWLEY F, Mihalopoulos M, Gaglani S, Tewari AK, et al
    Prostate cancer in transgender women: considerations for screening, diagnosis and management.
    Br J Cancer. 2022 Oct 19. pii: 10.1038/s41416-022-01989.
    PubMed     Abstract available
    
    
    
44. GLUD EN, Rasmussen M, Zhang Y, Mandrup OA, et al
    Identification of a high-risk immunogenic prostate cancer patient subset as candidates for T-cell engager immunotherapy and the introduction of a novel albumin-fused anti-CD3 x anti-PSMA bispecific design.
    Br J Cancer. 2022 Oct 15. pii: 10.1038/s41416-022-01994.
    PubMed     Abstract available
    
    
    August 2022
45. GRAFF RE, Langlais CS, Van Blarigan EL, Pernar CH, et al
    Post-diagnostic health behaviour scores in relation to fatal prostate cancer.
    Br J Cancer. 2022 Aug 26. pii: 10.1038/s41416-022-01948.
    PubMed     Abstract available
    
    
    
46. KIMURA H, Mizuno K, Shiota M, Narita S, et al
    Prognostic significance of pathogenic variants in BRCA1, BRCA2, ATM and PALB2 genes in men undergoing hormonal therapy for advanced prostate cancer.
    Br J Cancer. 2022 Aug 19. pii: 10.1038/s41416-022-01915.
    PubMed     Abstract available
    
    
    
47. GREEN HD, Merriel SWD, Oram RA, Ruth KS, et al
    Applying a genetic risk score for prostate cancer to men with lower urinary tract symptoms in primary care to predict prostate cancer diagnosis: a cohort study in the UK Biobank.
    Br J Cancer. 2022 Aug 18. pii: 10.1038/s41416-022-01918.
    PubMed     Abstract available
    
    
    July 2022
48. SACHDEVA A, Hart CA, Kim K, Tawadros T, et al
    Non-canonical EphA2 activation underpins PTEN-mediated metastatic migration and poor clinical outcome in prostate cancer.
    Br J Cancer. 2022 Jul 22. pii: 10.1038/s41416-022-01914.
    PubMed     Abstract available
    
    
    June 2022
49. TRUJILLO B, Wu A, Wetterskog D, Attard G, et al
    Blood-based liquid biopsies for prostate cancer: clinical opportunities and challenges.
    Br J Cancer. 2022 Jun 17. pii: 10.1038/s41416-022-01881.
    PubMed     Abstract available
    
    
    May 2022
50. NAIR-SHALLIKER V, Bang A, Egger S, Yu XQ, et al
    Family history, obesity, urological factors and diabetic medications and their associations with risk of prostate cancer diagnosis in a large prospective study.
    Br J Cancer. 2022 May 24. pii: 10.1038/s41416-022-01827.
    PubMed     Abstract available
    
    
    
51. SALMINEN JK, Mehtola A, Talala K, Taari K, et al
    Anti-epileptic drugs and prostate cancer-specific mortality compared to non-users of anti-epileptic drugs in the Finnish Randomized Study of Screening for Prostate Cancer.
    Br J Cancer. 2022 May 3. pii: 10.1038/s41416-022-01817.
    PubMed     Abstract available
    
    
    April 2022
52. OWARI T, Tanaka N, Nakai Y, Miyake M, et al
    5-Aminolevulinic acid overcomes hypoxia-induced radiation resistance by enhancing mitochondrial reactive oxygen species production in prostate cancer cells.
    Br J Cancer. 2022 Apr 1. pii: 10.1038/s41416-022-01789.
    PubMed     Abstract available
    
    
    
53. RASMUSSEN M, Fredsoe J, Tin AL, Vickers AJ, et al
    Independent validation of a pre-specified four-kallikrein marker model for prediction of adverse pathology and biochemical recurrence.
    Br J Cancer. 2022;126:1004-1009.
    PubMed     Abstract available
    
    
    March 2022
54. SALBERG UB, Skingen VE, Fjeldbo CS, Hompland T, et al
    A prognostic hypoxia gene signature with low heterogeneity within the dominant tumour lesion in prostate cancer patients.
    Br J Cancer. 2022 Mar 24. pii: 10.1038/s41416-022-01782.
    PubMed     Abstract available
    
    
    February 2022
55. SLOOTBEEK PHJ, Kloots ISH, Smits M, van Oort IM, et al
    Correction to: Impact of molecular tumour board discussion on targeted therapy allocation in advanced prostate cancer.
    Br J Cancer. 2022 Feb 24. pii: 10.1038/s41416-022-01765.
    PubMed    
    
    
    January 2022
56. RANA S, Valbuena GN, Curry E, Bevan CL, et al
    MicroRNAs as biomarkers for prostate cancer prognosis: a systematic review and a systematic reanalysis of public data.
    Br J Cancer. 2022 Jan 12. pii: 10.1038/s41416-021-01677.
    PubMed     Abstract available
    
    
    December 2021
57. NYBERG T, Tischkowitz M, Antoniou AC
    BRCA1 and BRCA2 pathogenic variants and prostate cancer risk: systematic review and meta-analysis.
    Br J Cancer. 2021 Dec 28. pii: 10.1038/s41416-021-01675.
    PubMed     Abstract available
    
    
    
58. MCHUGH J, Saunders EJ, Dadaev T, McGrowder E, et al
    Prostate cancer risk in men of differing genetic ancestry and approaches to disease screening and management in these groups.
    Br J Cancer. 2021 Dec 18. pii: 10.1038/s41416-021-01669.
    PubMed     Abstract available
    
    
    
59. SLOOTBEEK PHJ, Kloots ISH, Smits M, van Oort IM, et al
    Impact of molecular tumour board discussion on targeted therapy allocation in advanced prostate cancer.
    Br J Cancer. 2021 Dec 15. pii: 10.1038/s41416-021-01663.
    PubMed     Abstract available
    
    
    November 2021
60. SRIVASTAVA SK, Khan MA, Anand S, Zubair H, et al
    MYB interacts with androgen receptor, sustains its ligand-independent activation and promotes castration resistance in prostate cancer.
    Br J Cancer. 2021 Nov 26. pii: 10.1038/s41416-021-01641.
    PubMed     Abstract available
    
    
    
61. WEN YC, Liu CL, Yeh HL, Chen WH, et al
    PCK1 regulates neuroendocrine differentiation in a positive feedback loop of LIF/ZBTB46 signalling in castration-resistant prostate cancer.
    Br J Cancer. 2021 Nov 24. pii: 10.1038/s41416-021-01631.
    PubMed     Abstract available
    
    
    
62. RAMIREZ-GARRASTACHO M, Berge V, Line A, Llorente A, et al
    Potential of miRNAs in urinary extracellular vesicles for management of active surveillance in prostate cancer patients.
    Br J Cancer. 2021 Nov 22. pii: 10.1038/s41416-021-01598.
    PubMed     Abstract available
    
    
    
63. RAMIREZ-GARRASTACHO M, Bajo-Santos C, Line A, Martens-Uzunova ES, et al
    Extracellular vesicles as a source of prostate cancer biomarkers in liquid biopsies: a decade of research.
    Br J Cancer. 2021 Nov 22. pii: 10.1038/s41416-021-01610.
    PubMed     Abstract available
    
    
    
64. HATANO K, Yoneyama T, Hatakeyama S, Tomiyama E, et al
    Simultaneous analysis of serum alpha2,3-linked sialylation and core-type fucosylation of prostate-specific antigen for the detection of high-grade prostate cancer.
    Br J Cancer. 2021 Nov 20. pii: 10.1038/s41416-021-01637.
    PubMed     Abstract available
    
    
    
65. NA R, Wei J, Sample CJ, Gielzak M, et al
    The HOXB13 variant X285K is associated with clinical significance and early age at diagnosis in African American prostate cancer patients.
    Br J Cancer. 2021 Nov 19. pii: 10.1038/s41416-021-01622.
    PubMed     Abstract available
    
    
    September 2021
66. YU H, Xie M, Meng Z, Lo CY, et al
    Endolysosomal ion channel MCOLN2 (Mucolipin-2) promotes prostate cancer progression via IL-1beta/NF-kappaB pathway.
    Br J Cancer. 2021 Sep 21. pii: 10.1038/s41416-021-01537.
    PubMed     Abstract available
    
    
    
67. KAKOURATOS C, Kalamida D, Lamprou I, Xanthopoulou E, et al
    Apalutamide radio-sensitisation of prostate cancer.
    Br J Cancer. 2021 Sep 1. pii: 10.1038/s41416-021-01528.
    PubMed     Abstract available
    
    
    
68. LIU Z, Thong MSY, Doege D, Koch-Gallenkamp L, et al
    Prevalence of benefit finding and posttraumatic growth in long-term cancer survivors: results from a multi-regional population-based survey in Germany.
    Br J Cancer. 2021;125:877-883.
    PubMed     Abstract available
    
    
    July 2021
69. DE GIORGI U, Sansovini M, Severi S, Nicolini S, et al
    Circulating androgen receptor gene amplification and resistance to (177)Lu-PSMA-617 in metastatic castration-resistant prostate cancer: results of a Phase 2 trial.
    Br J Cancer. 2021 Jul 31. pii: 10.1038/s41416-021-01508.
    PubMed     Abstract available
    
    
    
70. ZHAO Z, Zhao S
    Reply to Comment on "miR-199b-5p-DDR1-ERK signalling axis suppresses prostate cancer metastasis via inhibiting epithelial-mesenchymal transition".
    Br J Cancer. 2021 Jul 20. pii: 10.1038/s41416-021-01493.
    PubMed    
    
    
    
71. AHMAD F, Cherukuri MK, Choyke PL
    Metabolic reprogramming in prostate cancer.
    Br J Cancer. 2021 Jul 14. pii: 10.1038/s41416-021-01435.
    PubMed     Abstract available
    
    
    
72. SUI Y, Hu W, Zhang W, Li D, et al
    Insights into homeobox B9: a propeller for metastasis in dormant prostate cancer progenitor cells.
    Br J Cancer. 2021 Jul 10. pii: 10.1038/s41416-021-01482.
    PubMed     Abstract available
    
    
    June 2021
73. SJOBERG HT, Philippou Y, Magnussen AL, Tullis IDC, et al
    Tumour irradiation combined with vascular-targeted photodynamic therapy enhances antitumour effects in pre-clinical prostate cancer.
    Br J Cancer. 2021 Jun 21. pii: 10.1038/s41416-021-01450.
    PubMed     Abstract available
    
    
    
74. LAN T, Park Y, Colditz GA, Liu J, et al
    Adolescent animal product intake in relation to later prostate cancer risk and mortality in the NIH-AARP Diet and Health Study.
    Br J Cancer. 2021 Jun 16. pii: 10.1038/s41416-021-01463.
    PubMed     Abstract available
    
    
    
75. CHEN F, Han Y, Kang Y
    Bone marrow niches in the regulation of bone metastasis.
    Br J Cancer. 2021;124:1912-1920.
    PubMed     Abstract available
    
    
    May 2021
76. CRISTOBAL I, Santos A, Rubio J, Rojo F, et al
    Comment on "miR-199b-5p-DDR1-ERK signalling axis suppresses prostate cancer metastasis via inhibiting epithelial-mesenchymal transition".
    Br J Cancer. 2021 May 19. pii: 10.1038/s41416-021-01433.
    PubMed    
    
    
    
77. WOKOLORCZYK D, Kluzniak W, Stempa K, Rusak B, et al
    PALB2 mutations and prostate cancer risk and survival.
    Br J Cancer. 2021 May 18. pii: 10.1038/s41416-021-01410.
    PubMed     Abstract available
    
    
    
78. FILON M, Gawdzik J, Truong A, Allen G, et al
    Tandem histone methyltransferase upregulation defines a unique aggressive prostate cancer phenotype.
    Br J Cancer. 2021 May 11. pii: 10.1038/s41416-021-01398.
    PubMed     Abstract available
    
    
    
79. AMADOU A, Freisling H, Jenab M, Tsilidis KK, et al
    Prevalent diabetes and risk of total, colorectal, prostate and breast cancers in an ageing population: meta-analysis of individual participant data from cohorts of the CHANCES consortium.
    Br J Cancer. 2021;124:1882-1890.
    PubMed     Abstract available
    
    
    April 2021
80. EMOND JP, Lacombe L, Caron P, Turcotte V, et al
    Urinary oestrogen steroidome as an indicator of the risk of localised prostate cancer progression.
    Br J Cancer. 2021 Apr 7. pii: 10.1038/s41416-021-01376.
    PubMed     Abstract available
    
    
    February 2021
81. BARCLAY ME, Abel GA, Greenberg DC, Rous B, et al
    Socio-demographic variation in stage at diagnosis of breast, bladder, colon, endometrial, lung, melanoma, prostate, rectal, renal and ovarian cancer in England and its population impact.
    Br J Cancer. 2021 Feb 9. pii: 10.1038/s41416-021-01279.
    PubMed     Abstract available
    
    
    December 2020
82. AMERATUNGA M, Brana I, Bono P, Postel-Vinay S, et al
    First-in-human Phase 1 open label study of the BET inhibitor ODM-207 in patients with selected solid tumours.
    Br J Cancer. 2020;123:1730-1736.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Prostate Cancer is free of charge.